Vbx-016

Vbx-016 is a therapeutic cancer vaccine developed by Vaxon Biotech. It is a polypeptide composed of four optimized cryptic peptides derived from four different universal tumor antigens—CEA, MAGE, TERT, and HER-2/neu. The vaccine is designed for use in patients expressing the HLA-B7 molecule, which is present in approximately 20–25% of the human population. Its mechanism of action involves immunostimulation, specifically stimulating T lymphocytes to target tumor cells. The product aims to broaden the proportion of cancer patients who can benefit from peptide-based immunotherapy by targeting multiple universal tumor antigens[1][2][4].